Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

http://www.businessweek.com/ap/2012-11-06/abbott-labs-says-abbvie-places-14-dot-7b-in-debt

AP News

Abbott Labs says AbbVie places $14.7B in debt


NEW YORK (AP) — Abbott Laboratories Inc. said Tuesday its branded drug business priced a $14.7 billion private placement of debt.

The company said AbbVie sold $3.5 billion in senior notes due in 2015, $4 billion due in 2017, $1 billion due in 2018, $3.1 billion due in 2022, $2.6 billion due in 2042, and $500 million in floating rate senior notes due in 2015. The placement is expected to close on Thursday.

By the end of 2012 AbbVie will become a separate publicly-traded company focusing on branded pharmaceuticals like its anti-inflammatory drug Humira. Abbott Laboratories will have a more predictable business built around nutritional formula, generic drugs and heart stents.

Shares of North Chicago, Ill.-based Abbott rose 10 cents to $65.14 in afternoon trading.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus